Brief: SynAct: Initial Data From First Part Of Phase II Study Within RA

SynAct Pharma AB

05/05/2020 06:57

May 5 (Reuters) - SynAct Pharma AB  SYNACT.TE :
    * SYNACT PRESENTS INITIAL DATA FROM THE FIRST PART OF THE
PHASE II
STUDY WITHIN RA AND GIVES AN UPDATE ON ITS PROGRESSION
    * FIRST OF TWO TESTED DOSES (50 MG) IDENTIFIED TO BE SAFE
AND
WELL-TOLERATED
    * BLINDED REVIEW REVEALED THAT PATIENTS IN STUDY FORM TWO
GROUPS
BASED ON CHANGES IN THEIR CLINICAL DISEASE ACTIVITY INDEX
    * NOW INITIATES NEXT DOSE LEVEL (100 MG)
    * DESPITE COVID-19 UNCERTAINTIES, SYNACT PHARMA EXPECTS THAT
CASH
ON HAND AND ADDITIONAL FUNDS FROM EXERCISE OF OPTIONS (TO2) IN
JULY 2020, WILL BE SUFFICIENT TO SECURE CONTINUED CLINICAL
DEVELOPMENT OF AP1189

Source text for Eikon:  ID:nWkr8NXPjb 
Further company coverage:  SYNACT.TE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))